The addition of ISF35 overcomes the primary resistance to the checkpoint blockade antibodies, anti-PD-1 and anti-CTLA-4, and generates potent systemic antitumor T cell immunity that eradicates the injected tumor as well as distant, uninjected tumors, including the brain. The gene discussed is CTLA4; the disease is neoplasm.